the project grant program supports small-budget proposals for research projects in the history of medicine and allied disciplines such as science and technology studies, sociology, anthropology, and classics. projects must strive to advance the history of health, healthcare and disease, or the education of health professionals.

the ams postdoctoral fellowship provides support to promising researchers at a pivotal time in their careers. candidates should be embarking on a period of full-time post-phd degree studies and wish to add to their experience by engaging in research in canada or abroad. the fellowships are intended for emerging scholars to complete work already started on projects featuring the study, analysis, and interpretation of past practices, philosophies, and/or epistemologies related to human health, health care and/or disease, or the education of health professionals, or to begin a new project in the field.

with support from the canada life assurance co., we are pleased to offer two official awards, along with possible honorary mentions, to canadian organizations and collaborations. winners will be celebrated in the following ways:

• winners will be showcased in a public webinar hosted by the canadian observatory on homelessness and a way home canada.
• winners will be invited to share their work in conference presentations as opportunities arise.
• winners will be invited to join the national learning community on youth homelessness, if they are not already members.
• winners will receive a mini case study of their initiative, produced by research and communications staff at the canadian observatory on homelessness. the case studies will be published in the homeless hub newsletter, with a national and international reach of more than 18,000 subscribers.
• winners will be showcased in an updated edition of the roadmap for the prevention of youth homelessness.
• winners may be eligible to receive professional evaluation and public policy support for their initiatives, depending on the context and identified needs/opportunities.

priority will be placed on programs or initiatives that are:

• proactive, rather than reactive, approaches to youth homelessness, from a preventative and rights-based lens
• demonstrating significant impacts in the lives of vulnerable youth aged 13-24 years old
• delivering programs or services aimed at preventing youth homelessness that align with one or more elements of prevention from the roadmap for the prevention of youth homelessness

organizations may self-nominate their own program or initiative, or nominate another organization or initiative.

if you are interested in being nominated for this award, please contact dr. batia stolar, associate vice-president, research & graduate studies, at avp.research@lakeheadu.ca

this request is designed to solicit proposals to the strategic investment fund that will leverage kbhn funds and network expertise in new ventures with the potential to generate impact and value for end users and stakeholders. the expected outputs of these projects could include, but are not limited to, changes in practice or policy, advancing new technologies or establishing new applications for existing technologies, and expanding or scaling direct supports for children and families.

the canada council for the arts can help propel the careers of outstanding researchers through its prestigious killam prizes. we are pleased to announce that the 2022 competition is now underway!

five (5) prizes are awarded annually – one in each of the disciplines of engineering, health sciences, humanities, natural sciences, and social sciences. these career achievement awards recognize substantial and distinguished contribution, over a significant period, to scholarly research.

value: $100,000 each
how to qualify: nominate a candidate to the canada council for the arts
deadline: 30 june, 2021
for further information: see the guidelines.

we have also enabled nominations to be submitted electronically through a dedicated email address:
killam-prizes@canadacouncil.ca.

if you are interested in being nominated for this award, please contact dr. batia stolar, associate vice-president, research & graduate studies, at avp.research@lakeheadu.ca  

the fy21 defense appropriations act provides funding to the department of defense kidney cancer research program (kcrp) to support research of exceptional scientific merit in the area of kidney cancer.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 kcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy21 kcrp must address one or more of the following focus areas:

• conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors and the prevention of kidney cancer.
• identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
• define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
• develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations and drug delivery systems.
• identify and implement strategies to improve the quality of life of patients.
• identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.

https://cdmrp.army.mil/funding/kcrp

concept award – letter of intent due june 22, 2021

idea development award – preproposal due june 15, 2021

modified for fy21

established investigators:

independent investigators at or above the level of assistant professor (or equivalent) and 10 years or more from a terminal degree; or

early-career investigators:

investigators at the level of assistant professor, instructor, or assistant research professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission.

• supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

• innovation and impact are the most important review criteria.

• different funding options, based on the scope of the proposed research, are available with compelling justification.

• preliminary data are required.

• clinical trials are not allowed.

maximum funding of $600,000 in direct costs (plus indirect costs).

• period of performance not to exceed 3 years.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

early detection studies option:

• maximum funding of $650,000 in direct costs (plus indirect costs).

• period of performance not to exceed 3 years.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

population science and prevention studies option:

• maximum funding of $2 million in direct costs (plus indirect costs).

• period of performance not to exceed 4 years.

postdoctoral and clinical fellowship award – letter of intent due june 22, 2021

translational research partnership award

the initiating principal investigator (pi) must be at or above the level of assistant professor or equivalent.

the partnering pi must be at or above the level of assistant professor or equivalent.

postdoctoral fellows are not eligible to be partnering pis.

• supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

• supports translational correlative studies.

• preliminary data are required.

• clinical trials are not allowed.

• maximum funding of $750,000 for direct costs (plus indirect costs).

• maximum period of performance is 3 years.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507

help@ebrap.org

the fy21 defense appropriations act provides funding to the department of defense bone marrow failure research program (bmfrp) to support research of exceptional merit that focus on bone marrow failure diseases. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 bmfrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

the objective of the fy21 bmfrp is to fund scientifically meritorious research focused on bmf diseases. investigator‐initiated research is encouraged in the areas of congenital or acquired bmf. studies focused on bmf syndromes and their progression to other malignancies, such as leukemia, are acceptable. however, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. stem cell biology studies and translational projects, including bone marrow transplantation studies, should be clearly related to bmf diseases.

https://cdmrp.army.mil/funding/bmfrp

idea development award – preproposal due july 9, 2021

• established investigator: independent investigators at or above the level of associate professor (or equivalent) or an assistant professor (or equivalent) with 10 years or more from his/her first faculty appointment (or equivalent) by the application submission deadline.
• early career investigators: independent investigators at the level of assistant professor (or equivalent), and within 10 years from his/her first faculty appointment (or equivalent) by the application submission deadline.
• supports innovative ideas and high-impact approaches based on scientifically sound evidence in order to move toward the vision to understand and cure bone marrow failure (bmf) diseases.
• proposed research should have a high probability of revealing new avenues of investigation.
• research project should include a well–formulated, testable hypothesis and a well-developed and articulated research approach.
• must address at least one of the fy21 bmfrp ida focus areas.
• strong bmf research team.
• may include relevant preliminary data.
• clinical trials are not allowed.
• translational potential should be considered and described.
• pre-application is required; application is by invitation only.
  • the maximum period of performance is 3 years.
• the maximum allowable funding for the entire period of performance is $450,000 in direct costs (plus indirect costs).

investigator-initiated research award (iira) – preproposal due july 9, 2021

investigators at or above the level of assistant professor (or equivalent) by the application submission deadline.

• two funding levels of intent:

Ø  funding level 1: supports studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in bmf research, patient care, and/or quality of life. correlative studies to existing clinical trials/studies are encouraged.

translational potential should be considered and described.

• funding level 2: investigational new drug (ind)-enabling efforts the proposed studies should be empirical in nature, product driven, and focused on the accumulation of data to support an ind application to the u.s. food and drug administration.  applicants are required to identify lead bmf therapy candidate(s), and transition plans should be considered and adequately described.
• emphasis on research approach and impact.
• strong bmf research team.
• preliminary data required.
• clinical trials are not allowed.
• must address at least one of the fy21 bmfrp iira focus areas.
• partnering pi option: allows two pis, termed initiating and partnering pis, to collaborate on a single application.

pre-application is required; application is by invitation only

funding level 1:

• the maximum period of performance is 3 years.
• maximum funding of $600,000 in direct costs (plus indirect costs).

funding level 2: ind-enabling efforts

• the maximum period of performance is 4 years.
• maximum funding of $800,000 in direct costs (plus indirect costs).

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the bmfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

he fy21 defense appropriations act provides funding to the department of defense lupus research program (lrp) to support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 lrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

applications submitted to the fy21 lrp must address one or more of the following focus areas:

• understanding how lupus disease heterogeneity impacts risk of disease, disease presentation, clinical course, and outcomes; using a diverse range of research disciplines including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment studies, health economics, socioeconomic studies, environmental studies, and epidemiological studies.
• understanding mechanisms of lupus disease, using mechanistic studies, strategies, and technologies including, but not limited to, informative, rare patients.
• determining the pathobiology of end organ injury lupus disease in target human tissues.
• improving quality of life for individuals living with lupus including, but not limited to, addressing social determinants of health, access to healthcare resources, outcomes research, patient-reported outcomes, symptom and disease control, comparative effectiveness research, and issues and challenges that, when addressed, make day-to-day living with lupus easier and life more fulfilling.
• understanding the underlying genetic and epigenetic components and gene-environment interactions of lupus and how they may relate to clinical disease characteristics, variations, and differences in response to therapies using functional genomic studies.

applications submitted to the fy21 lrp transformative vision award must address the following focus area:

• design and implement an intervention including, at the individual and/or healthcare system level, improving quality of life for, but not limited to, access to healthcare resources, outcomes research, symptom and disease control, comparative effectiveness research, and issues and challenges that, when addressed, make day-to-day living with lupus easier and life more fulfilling.

https://cdmrp.army.mil/funding/lrp

idea award – letter of intent due august 24, 2021

investigators at or above the level of postdoctoral fellow (or equivalent)

• supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus.
• must address one of the fiscal year 2021 (fy21) lrp focus areas.
• emphasis is on innovation
• clinical trials are not allowed
• preliminary data are not required.
• the maximum allowable funding for the entire period of performance is $300,000 for total costs (direct plus indirect costs)
• the maximum period of performance is 2 years

impact award – letter of intent due august 24, 2021

independent investigators at or above assistant professor (or equivalent)

• supports high-risk/high-reward research which, if successfully addressed, has the potential to make a major impact in lupus research
• emphasis is on impact
• must address one of the fy21 lrp focus areas
• clinical trials are not allowed
• preliminary data are encouraged but not required
• the maximum allowable funding for the entire period of performance is $750,000 for total costs (direct plus indirect costs)
• the maximum period of performance is 4 years

transformative vision award – letter of intent due august 24, 2021

independent investigators at or above assistant professor (or equivalent)

• supports research that will have an intervention at the individual and/or healthcare system level, which will result in near-term impact on the health-related quality of life of persons living with lupus
• emphasis is on near-term impact to quality of life
• must address the fy21 lrp tva focus area
• human subject research and clinical trials are allowed.
• preliminary data are required
• animal studies are not allowed.
• partnering principal investigators  (pi) option allows one initiating investigator and a maximum of two partnering pis 
• new – the research team must include one of more consumer advocate(s).
• the maximum allowable funding for the entire period of performance is $2.5 million for total costs (direct plus indirect costs)
• the maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the lrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the specific objective of this funding opportunity is:

• to improve the efficacy of personalized treatment of cancer patients through the development of new tools and targeted immunotherapy strategies, based on a better understanding of tme functions and of their impact on the disease course.